The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease

AIDS

Volumn 10, Issue 8, 1996, Pages 867-880

  Darbyshire, Janet ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiviral therapy; Clinical trial; Didanosine; Randomized trial; Therapy

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EUROPE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; XEROSTOMIA;

EID: 8944223522     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199607000-00010     Document Type: Article

References (29)

1. 9/l or less. Arch Intern Med 1992, 152:2286-2292.
2. Richman DD, Fischl MA, Crieco MH, et al.: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:192-197.
3. Pinching AJ, HelbertM, Peddle B, et al.: Clinical experience with zidovudine for patients with AIDS and ARC. J Infect 1989, 18 (suppl1):33-40.
4. Cooley TP, Kunches LM, Saunders CA, ef al.: Treatment of AIDS and AIDS related complex with 2′,3′-dideoxyinosine given once daily. Rev Infect Dis 1990,12 (suppl 5):S552-S560.
5. Yarchoan R, Mitsuya H, Thomas RV, ef al.: In vivo activity against HIV and favourable toxicity profile of 2′,3′-dideoxyinosine. Science 1989, 245:412-415.
6. Yarchoan R, Pluda JM, Thomas RV, et al.: Long term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex, iancef 1990, 336:526-29.
7. Cooley TP, Kunches LM, Saunders ÇA, et al.: Once daily adminis-tration of 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N Eng/7 Med 1990, 322:1340-1345.
8. Lambert JS, Seidlin M, Reichman RC, eraJ.: 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N EnglJ Med 1990, 322:1333-1340.
9. Bouvet E, Casaline E, Prévost MH, Vachon F: Fatal case of 2′,3′ dideoxyinosine-associated pancreatitis [letter]. Lancet 1990, 336:1515.
10. Pocock SJ: Clinical Trials: A Practical Approach. Chichester: John Wiley; 1988.
11. Barry M, Howe JL, Ormesher S, et al.: Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol 1994, 37:421-426.
12. Knupp CA, Stancato FA, Papp EA, Barbhalya RH: Quantitation of didanosine in human plasma and urea by high performance liquid chromatography. j Chromatog BiomedApp11990, 533:282-290.
13. Centers for Disease Control: Revision of the CDC surveillance case definition for the acquired immune deficiency syndrome. MMWR 1987, 36(suppl 1S):1-15.
14. Price RW, Brew BJ: The AIDS dementia complex. J Infect Dis 1988,158:1079-1083.
15. Boccellari AA, Dilley JW: Management and residential placement problems of patients with HIV related cognitive impairment. Hosp Community Psychiatry 1992, 43:32-37.
16. Rosser RM, Watts VC: The measurement of hospital output. Int J Epidemiol 1972,1: 361-368.
17. Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomised clinical trials requiring prolonged observation of each participant. II: Analysis and examples. BrJ Cancer 1977, 35:1-39.
18. Wei LJ, Johnson WE: Combining dependent tests with incomplete repeated measurements. Biometrika 1985, 72:359-364.
19. Dawson JD, Lagakos SW: Analyzing laboratory marker changes in AIDS clinical trials. J Acquir Immune Defic Syndr 1991, 4:667-576.
20. Allan JD, de Gruttola V, Cross A, et al.: Executive Summary of ACTG 118; 1992.
21. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-882.
22. Seidlin M, Lambert JS, Dolin R, Valentine FT: Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS 1992,6:831-835.
23. Maxson CJ, Creenfield SM, Turner JL: Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired imunodeficiency syndrome. Am J Castroenterol 1992, 87:708-713.
24. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
25. Dolin R, Amato DA, Fischl MA, et al.: Zidovudine compared with didanosine in patients with advanced HIV type-1 infection and little or no previous experience with zidovudine. Arch Int Med 1995,155:961-974.
26. Abrams D, Goldman A, Launer C, et al.: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994, 330:657-662.
27. st May, 1995. Presented at the V European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, September 1995.
28. 3. Presented at the V European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, September 1995.
29. 3. Third Conference on Retroviruses and Opportunistic Infections. Washington, JanuaryFebruary 1996 [abstract LB4).